{
    "nctId": "NCT05305092",
    "briefTitle": "Assessment of Brain Cognitive Impairment in Breast Cancer",
    "officialTitle": "Integrated PET/MRI Study of Cognitive Impairment in Premenopausal Breast Cancer Patients After Chemotherapy or Endocrine Therapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Chemo-brain, Endocrine Therapy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "Change of gray matter volume of whole brain",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with primary stage I-II breast cancer.\n* Premenopausal women (menopausal status determined by National Comprehensive Cancer Network Breast Cancer Guidelines criteria).\n* No treatment other than surgery has been started (if neoadjuvant chemotherapy is required before surgery, enroll before chemotherapy starts).\n* Eastern Cooperative Oncology Group score of 0-1 points.\n* Can understand and complete various scales.\n* Right handedness.\n* Female subjects of childbearing potential must be willing to use a medically-approved high-efficiency contraceptive method (eg, intra-uterine device, birth control pill, or condom) for the duration of the study.\n* Sign the informed consent and voluntarily participate in this clinical observation.\n\nExclusion Criteria:\n\n* Central nervous system (CNS) disease, history of malignancy, chronic loss of consciousness, head trauma, and any disease affecting cognitive function.\n* Current or former epilepsy, dementia, or learning disabilities.\n* Past psychiatric history.\n* Past history of malignancy.\n* MRI related contraindications: pacemakers, defibrillators, hearing aids, insulin pumps, drug dose control devices and other metal implants; patients with severe hyperthermia; patients with claustrophobia.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}